Amyotrophic lateral sclerosis is a neurodegenerative disease characterised by selective degeneration of motor neurons. This process results in deterioration of muscle strength in the limbs and bulbar ...

A toxic version of a certain protein may affect brain, spinal cord and skeletal muscle tissues differently, leading to the ...

Eisai Co., Ltd. announced today that amyotrophic lateral sclerosis (ALS) treatment “Rozebalamin® for Injection 25 mg” ...

RNS60 is an experimental therapy designed to boost the formation of new mitochondria and restore energy production in nerve ...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MA ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that twelve presentations following expansive research in amyotrophic lateral sclerosis (ALS) will be shared as part of the Northeast ...

Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to ...

Sanofi stopped a Phase 2 study of oditrasertib in relapsing and progressive MS after it failed to lower blood NfL levels ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

A team of researchers from Penn State College of Medicine found that misfolded versions of a protein exhibit tissue-specific toxicity linked to cell degeneration that may be linked to the development ...

True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics after shareholders ...

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...